News - Xtant Medical

Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025

November 4, 2025

BELGRADE, Mont. , Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the

Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO, and Scott Neils, CFO,

Xtant Medical Reports Second Quarter 2025 Financial Results

August 12, 2025

Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million , Representing Growth of 11%-15% over FY24 BELGRADE, Mont. , Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.

Xtant Medical to Attend the CG 45th Annual Growth Conference

August 6, 2025

BELGRADE, Mont. , Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO will be

Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025

August 5, 2025

BELGRADE, Mont. , Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the

Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine

July 8, 2025

Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont. , July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc.

Xtant Medical Announces the Launch of OsteoFactor Pro™

May 28, 2025

Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont. , May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today

Xtant Medical Reports First Quarter 2025 Financial Results

May 12, 2025

Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical

Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

May 6, 2025

BELGRADE, Mont. , May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the

Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

April 23, 2025

BELGRADE, Mont. , April 23, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of Trivium™ , a premium,

Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%

April 16, 2025

Healthcare Focused Long-term Investors Support Strategic Vision Accelerating Shift to Higher-Margin Orthobiologics Supported by New Product Launches BELGRADE, Mont. , April 16, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused

Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial Results

March 6, 2025

Full Year 2024 Revenue Growth of 28% Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / March 6, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for